The Global HPV Testing and Pap Test Market size is expected to reach $7.1 billion by 2027, rising at a market growth of 33.5% CAGR during the forecast period. Pap tests and HPV Testing both are included in cervical cancer screening which is a crucial part of a woman’s routine health checkup as it can discover cancer of abnormalities that could result in cancer of the cervix. It is suggested that a woman should undergo a Pap test every 3 years starting from the age of 21. Also, it is further recommended that women between the ages of 30 to 65 should undergo Pap and HPV every after 5 years or a Pap test in 3 years. Women having some risk factors may require more often screening or to keep on screening themselves even after the age of 65 years.
Some of the determinants that boost the demand & growth of HPV Testing and Pap Test are constant technological developments, a rising number of cervical cancer screening programs, and growing cases of cervical cancer. On the other hand, the global COVID-19 crisis and the imposition of various lockdown norms and restrictions to keep people in their homes have substantially decreased routine cancer screenings.
Interruptions in cancer screening services have been observed in a majority of settings as a result of the global coronavirus crisis. Guidelines for cancer screening activities are generally created after systematic and careful consideration of the optimally available evidence to provide high-quality care and to cut down variability in clinical practice. Though, the beginning of the COVId-19 pandemic needed an instant response at a time when the duration of the pandemic could not be predicted and the nature of the virus was still majorly unidentified. In the majority of settings, the consequence of this situation was a time-restricted deferment of services. These disturbances are anticipated to cause highly advanced cancer diagnoses and deaths in the next few years.
Screening services have now restarted to some extent in most of the countries; though, subsequent the deadly COVId-19 outbreak continues to create disruption in healthcare provisions. In spite of the approval of different secure and extremely effective COVID-19 vaccines, supply constraints have deferred their roll-out. Hence, the present disruptions to health care, in general, are expected to remain the same for some time. Therefore, the outbreak of COVID-19 pandemic has adversely affected the HPV Testing and Pap Test Market.
Based on Type, the market is segmented into Pap Test and HPV Testing. The Pap test segment procured the maximum revenue share of the global HPV Testing and Pap Test in 2020. This is credited to its large-scale implementation in various screening programs. In addition to it, the segment would witness a boost with the increasing number of initiatives to raise awareness regarding Pap tests.
Based on Application, the market is segmented into Cervical Cancer Screening, and Vaginal Cancer Screening. In 2020, the cervical cancer screening segment appeared as the leading segment in the HPV Testing and Pap Test Market by obtaining the highest revenue share. The segment would exhibit a promising CAGR during the forecast period. This growth and massive revenue share are credited to the increasing rates of cervical cancer in comparison to vaginal cancer.
Based on Product, the market is segmented into Consumables, Instruments, and Services. The consumables segment acquired the highest revenue share of the HPV Testing and Pap Test Market, thereby became a dominant segment in 2020. This is credited to its high and constant utilization in HPV and cervical screenings. Besides, the growth of the segment would be accelerated by the constant development activities by leading players in the market and the launch of unique consumables, like assays & kits, for high accuracy of diagnosis in HPV and Pap test.
Based on End Use, the market is segmented into Hospitals & Clinics, Laboratories and Other End Users. The hospitals and clinics segment obtained the maximum revenue share of the HPV Testing and Pap Test Market and thus, became the leading segment in 2020. This is credited to the fact that they act as primary care settings for diagnosis and treatment of all diseases, such as HPV infections and cervical cancer. In addition to it, the requirement for hospitals and clinics with superior diagnostic services has been boosted by a surge in healthcare spending around the globe and constant modification in the healthcare industry.
| Report Attribute | Details |
|---|---|
| Market size value in 2020 | USD 811.4 Million |
| Market size forecast in 2027 | USD 7.1 Billion |
| Base Year | 2020 |
| Historical Period | 2017 to 2019 |
| Forecast Period | 2021 to 2027 |
| Revenue Growth Rate | CAGR of 33.5% from 2021 to 2027 |
| Number of Pages | 259 |
| Number of Tables | 510 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Type, Application, Product, End Use, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America emerged as the leading region in the global HPV Testing and Pap Test Market by acquiring the maximum revenue share of it. The region would exhibit a similar trend even during the forecast period. Some of the catalysts for the growth of the regional market are increasing awareness regarding the early diagnosis of cervical cancer, well-planned screening guidelines, and supportive healthcare reimbursement policies.
Free Valuable Insights: Global HPV Testing and Pap Test Market size to reach USD 7.1 Billion by 2027
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Hologic, Inc., Quest Diagnostics, Incorporated, Seegene, Inc., Arbor Vita Corporation, Femasys, Inc., and Qiagen N.V.
By Type
By Application
By Product
By End Use
By Geography
The HPV testing and Pap test market size is projected to reach USD 7.1 billion by 2027.
Rising awareness regarding the various cervical cancer screening programs are driving the market in coming years, however, Limitations of Pap Tests have limited the growth of the market.
Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Hologic, Inc., Quest Diagnostics, Incorporated, Seegene, Inc., Arbor Vita Corporation, Femasys, Inc., and Qiagen N.V.
The present disruptions to health care due to COVID-19, in general, are expected to remain the same for some time. Therefore, the outbreak of COVID-19 pandemic has adversely affected the HPV Testing and Pap Test Market.
The services segment would be the fastest-growing segment during the forecast years. This is due to the launch of self and at-home HPV screening solutions to enhance the screening rates of cervical cancer in the major markets.
The expected CAGR of the HPV testing and Pap test market is 33.5% from 2021 to 2027.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 